基于“以不变应万变”的策略研发泛β属冠状病毒疫苗

Development of Pan-β-coronavirus Vaccines Using the“Non-changeable-against-changes”Strategy

21世纪以来,全球已发生3次由冠状病毒感染引起的高致病性传染病疫情。其中,新冠病毒疫情规模空前,已造成数百万人死亡,给人类社会带来巨大冲击。接种疫苗是防控传染病的有效方法之一。目前,大部分疫苗开发商选择“以变应变”的策略(使用最新变异株的抗原位点)开发新冠疫苗。然而,疫苗开发的速度远远赶不上病毒变异的速度。笔者团队坚持采用“以不变应万变”的策略(使用原始毒株蛋白中保守的抗原位点)研发高效广谱抗沙贝冠状病毒或β属冠状病毒疫苗,以期更好地应对新冠病毒变异株以及未来新发与再现的β属冠状病毒疫情。

In the past 20 years,the world has witnessed three major outbreaks of highly pathogenic coronavirus infectious diseases.Among them,the COVID-19 pandemic is unprecedented,resulting in millions of deaths and a tremendous impact on global health.Vaccination is a key measure in the prevention and control of infectious diseases.At present,most vaccine developers adopt a"changeable-against-change"strategy(i.e.,using antigenic sites of the latest variants)to develop COVID-19 vaccines.However,the speed of vaccine development lags far behind the pace of virus mutations.Our team has been adhering to a"non-changeable-against-changes"strategy(i.e.,using conserved antigenic sites in proteins of the original virus strain)to develop highly effective broad-spectrum pan-sarbecovirus orβ-coronavirus vaccines.This approach aims to better address the SARS-CoV-2 variants and future outbreaks of novel or recurringβ-coronavirus pandemics.